Frazier Life Sciences Acquisition Corp. II Form 424B4 — Oct 14, 2026
Frazier Life Sciences Acquisition Corp. II priced its IPO of 7,500,000 Class A ordinary shares at $10.00 per share, raising $75,000,000 in gross proceeds, with all of it deposited into a trust account at Continental Stock Transfer & Trust Company. Jefferies is the sole book-running manager, and shares are expected to trade on Nasdaq under symbol FLSC on or promptly after October 13, 2026. The company is a blank check SPAC sponsored by Frazier Life Sciences Holdings II LLC, targeting biotechnology business combinations within a 24-month completion window.
Key figures
- Founder Shares
- 1875000
- Gross Proceeds
- 75000000
- Offering Price
- 10
- Shares Offered
- 7500000
- Trust Account Deposit
- 75000000
- Redemption Cap Percent
- 15
- Completion Window Months
- 24
- Private Placement Shares
- 300000
- Proceeds Before Expenses
- 70500000
- Sponsor Ownership Percent
- 22.5
- Private Placement Proceeds
- 3000000
- Forward Purchase Commitment
- 25000000
- Founder Share Purchase Price
- 25000
- Underwriting Discount Total
- 4500000
- Forward Purchase Shares Minimum
- 2500000
- Underwriting Discount Per Share
- 0.6
- Post Offering Shares Outstanding
- 9675000
- Deferred Underwriting Commissions
- 3000000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.